22 recruiting, 7 active not recruiting, 1 completed, 1 not yet recruiting. 14 Phase 2, 13 Phase 3, 6 Phase 1, 2 Early Phase 1.
By phase and status
Follow Rilvegostomig: new trials by email Literature Review of Rilvegostomig trials Research Report on Rilvegostomig
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Local and Systemic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Advanced Gastric Cancer (RILVE Project) Rilvegostomig, Pembrolizumab - Advanced Gastric Cancer Phase 2 Not yet recruiting Vall d'Hebron Institute of Oncology 50 2026-10-01 2026-08-26 An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC Dato-DXd, Rilvegostomig, Durvalumab - High-risk Muscle Invasive Urothelial Carcinoma Phase 3 Recruiting AstraZeneca 915 2026-07-16 2026-07-22 Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 Sonesitatug vedotin, Rilvegostomig, Nivolumab - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Phase 3 Recruiting AstraZeneca 2130 2026-02-03 2026-10-16 A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) Rilvegostomig, Durvalumab, Gemcitabine/Cisplatin - Biliary Tract Cancer Phase 3 Recruiting AstraZeneca 1100 2025-12-04 2026-09-28 A Platform Study in Non-Small Cell Lung Cancer (NSCLC) Rilvegostomig, Cisplatin, Carboplatin - Advanced or Metastatic Non-small Cell Lung Cancer Phase 1 / Phase 2 Recruiting AstraZeneca 152 2025-11-24 2026-10-01 A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) Rilvegostomig, Ramucirumab, Dato-DXd - Non-Small Cell Lung Cancer Phase 2 Recruiting AstraZeneca 278 2025-08-07 2026-10-15 A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors AZD6750, rilvegostomig - Melanoma, Non-small Cell Lung Cancer Phase 1 / Phase 2 Recruiting AstraZeneca 120 2025-07-29 2026-10-08 A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma Sonesitatug Vedotin, Rilvegostomig, Trastuzumab Deruxtecan (T-DXd) - Gastroesophageal Adenocarcinoma Phase 2 Recruiting AstraZeneca 100 2025-07-17 2026-10-16 Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma Tremelimumab, Rilvegostomig, Bevacizumab - Hepatocellular Carcinoma Phase 3 Recruiting AstraZeneca 1220 2025-05-06 2026-10-13 A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer Rilvegostomig, Pembrolizumab - Carcinoma, Non-Small Cell Lung Phase 3 Recruiting AstraZeneca 830 2025-04-10 2026-09-25 DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab - Endometrial Cancer Phase 3 Recruiting AstraZeneca 600 2025-03-27 2026-10-13 A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab - HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Phase 3 Recruiting AstraZeneca 840 2025-03-01 2026-10-16 Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer Trastuzumab deruxtecan, Capecitabine, Rilvegostomig - Stomach Neoplasms Phase 2 Recruiting Jeeyun Lee 100 2025-01-22 2026-07-01 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC Rilvegostomig, Pembrolizumab, Carboplatin - Non-squamous Non-small Cell Lung Cancer Phase 3 Recruiting AstraZeneca 1160 2024-11-27 2026-09-23 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Rilvegostomig, Pembrolizumab, Carboplatin - Non-small Cell Lung Cancer Phase 3 Recruiting AstraZeneca 1160 2024-11-18 2026-09-18 A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features Datopotamab Deruxtecan, Rilvegostomig, Carboplatin - Non-small Cell Lung Cancer Phase 3 Active not recruiting AstraZeneca 25 2024-10-15 2026-09-23 Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer Gemcitabine, Cisplatin, Durvalumab - Biliary Tract Cancer Phase 3 Recruiting AstraZeneca 620 2024-08-12 2026-10-13 PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC Rilvegostomig, Volrustomig, Sabestomig - Head and Neck Squamous Cell Carcinoma Early Phase 1 Completed Presage Biosciences 17 2024-05-22 2026-06-26 Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations Datopotamab Deruxtecan, Rilvegostomig, Pembrolizumab - Non-Small Cell Lung Cancer Phase 3 Recruiting AstraZeneca 675 2024-04-11 2026-09-23 Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) Rilvegostomig, Placebo, Capecitabine - Biliary Tract Cancer Phase 3 Active not recruiting AstraZeneca 760 2023-12-04 2026-10-16
Showing 20 of 31. Sign in to see all of them.
Conditions studied Carcinoma, Non-Small-Cell Lung (11) · Stomach Neoplasms (8) · Biliary Tract Neoplasms (5) · Adenocarcinoma (3) · Squamous Cell Carcinoma of Head and Neck (3) · Adenocarcinoma Of Esophagus (2) · Carcinoma (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Renal Cell (2) · Endometrial Neoplasms (2) · Esophageal Neoplasms (2) · Gallbladder Neoplasms (2) · Head and Neck Neoplasms (2) · Melanoma (2) · Parkinson Disease 4, Autosomal Dominant Lewy Body (2)
Sponsors AstraZeneca (26) · Presage Biosciences (2) · CCTU- Cancer Theme (1) · Jeeyun Lee (1) · Vall d'Hebron Institute of Oncology (1)
Countries United States (28) · Japan (24) · South Korea (24) · Spain (24) · Taiwan (24) · China (22) · Italy (21) · Canada (19) · United Kingdom (19) · France (18) · Brazil (17) · Poland (17) · Turkey (Türkiye) (17) · Australia (16) · Belgium (15)
Top investigators Brent O'Carrigan (1) · David Jones, MD (1) · Enriqueta Felip, MD (1) · Grant D Stewart (1) · Jeeyun Lee, Ph, MD (1) · Suresh S. Ramalingam, MD (1) · Tina Cascone, MD (1)
Results publications PMID 34794412 , PMID 36923556 , PMID 38981998 , PMID 40341124 , PMID 40450142 , PMID 40759445 , PMID 40976544 , PMID 41369900 , PMID 41448488 , PMID 41669261
NIH funding 2023 (10), 2019 (1)